Phase I/II study of stereotactic radiation therapy and concurrent and adjuvant Sutent [sunitinib] (SU11248) as treatment for oligometastatic disease
Phase of Trial: Phase I/II
Latest Information Update: 24 Jul 2018
At a glance
- Drugs Sunitinib (Primary)
- Indications Cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Jul 2007 New trial record.